NCT06284564View on ClinicalTrials.gov

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Evolocumab

Given by SC

DRUG

Nivolumab

Given by IV

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Cancer Prevention Research Institute of Texas

OTHER

collaborator

United States Department of Defense

FED

lead

M.D. Anderson Cancer Center

OTHER

NCT06284564 - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | Biotech Hunter | Biotech Hunter